Cutaneous T-cell lymphoma (CTCL) is an umbrella term used to describe several related lymphomas. The most common forms—and the first to be identified—are Mycosis fungoides and Sézary syndrome. The term, however, now includes a number of additional diseases characterized by malignant T cell expansions.
MF is the most common form of CTCL, accounting for 50% to 60% of all cases.17,18
MF has an indolent course, with slow progression over many years or decades. It typically progresses from patches to plaques, and eventually to tumor development.17
While MF is generally limited to epidermal involvement, in some patients the disease slowly spreads to the lymph nodes and internal organs.17
SS is an aggressive form of disease that affects approximately 5% of patients with CTCL.18
Other, less common forms of CTCL may be categorized according to their clinical form—indolent and aggressive. THERAKOS™ Photopheresis has not been evaluated in these less common forms.
Aggressive clinical form
Specially designed for medical professionals to use in their practice.
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.